Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-299-8 | CAS number: 105-45-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicity to reproduction
Administrative data
- Endpoint:
- one-generation reproductive toxicity
- Remarks:
- based on test type (migrated information)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP - Guideline study.
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 998
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- GLP compliance:
- yes
Test material
- Reference substance name:
- Methyl acetoacetate
- EC Number:
- 203-299-8
- EC Name:
- Methyl acetoacetate
- Cas Number:
- 105-45-3
- Molecular formula:
- C5H8O3
- IUPAC Name:
- methyl 3-oxobutanoate
- Details on test material:
- - Name of test material (as cited in study report): methyl acetoacetate
- Physical state: transparent and colorless liquid
- Analytical purity: 99.4 %
- Lot/batch No.: Lot No. 602006
- Storage condition of test material: at low temperatures, protected from light
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories Japan, Inc
- Age at study initiation: 10-week old
- Weight at study initiation: 373.2 - 428.2 g (males) and 227.7 - 255.3 g (females)
- Fasting period before study: no data
- Housing: individually
- Diet (e.g. ad libitum): pellets (MF, manufactured by Oriental Yeast Co., Ltd.)
- Water (e.g. ad libitum): water containing sodium hypochlorite (approx. 2 ppm)
- Acclimation period: 13 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 24±2
- Humidity (%): 55±10
- Air changes (per hr): 13 - 15 times
- Photoperiod (hrs dark / hrs light): 12 h / 12 h
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
- Using Japanese Pharmacopoeia (JP) water for injection (manufactured by Otsuka Pharmaceutical Factory, Inc., Lot No. 6D77) as a medium, the test article was dissolved therein so that the concentrations were 1, 3 and 10 w/v% to prepare liquids to be administered. The resulting liquids to be administered were preserved at room temperature.
- Incidentally, the concentrations of the liquids to be administered were measured during the week of starting administration to confirm that they were within ±5 % of each preset value.
TREATMENT
- The test article was given through a gastric tube once daily to males for total 49 days (for a 14-day pre-mating period, followed by 35 days including mating period) and females throughout a 14-day pre-mating period, additional mating (max. 14 days) and gestation periods to day 3 of lactation.
- The defined dose level was 10 mL/kg, which was used to obtain individualized doses based on the latest body weights in the case of all males and a part of females (prior to and during mating period), or body weights on day 0 of gestation in the case of females after successful copulation. - Details on mating procedure:
- - As for females, vaginal smears were collected at a certain time every morning from 14 days before the beginning of mating (the starting day of administration) to the day when copulation was confirmed, in order to examine sexual cycle.
- As for mating, each one male and female (both 12-week old) were placed to cohabit for a night; and if any of sperms or vaginal plug was found in vaginal smear on the following morning, that day was defined as day 0 of gestation.
- Additionally, each mating was performed within the same group, and the mating period was set to maximum 2 weeks.
After the completion of mating period, number of days required for copulation, copulation rate [(Number of copulated animals/Number of cohabited animals) x 100] and gestation index [(Number of gestated animals/Number of copulated animals) x 100] were obtained.
- During gestation and lactation periods, the animals were placed one-by-one (including its own nursed offspring during lactation period) - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Before starting administration, it was ascertained that 0.1 and 20 w/v%-solutions, which were prepared according to this method, were stable at room temperature under diffused light for at least 8 days.
- Duration of treatment / exposure:
- Exposure period: males: 49 days; females: from day 14 prior mating until day 3 of lactation
Premating exposure period (males): 14 days
Premating exposure period (females): 14 days
Duration of test: males: 49 days; females ca. 42 days (premating period (14 days) + mating period (2 - 3 days) + gestation period (22 days) + 3 days of lactation - Frequency of treatment:
- daily
- Details on study schedule:
- - Number of generation studies: 1
Doses / concentrations
- Remarks:
- Doses / Concentrations:
100, 300 and 1000 mg/kg bw/d
Basis:
actual ingested
- No. of animals per sex per dose:
- 12
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Study design:
The test compound was administered orally to male and female rats in a pre-mating period, followed by additional days including mating period in the case of males, or continued administration throughout mating and gestation periods to day 3 postpartum in the case of females, in order to evaluate repeat dose toxicity to parental animals, as well as effects on fertility and development/growth of offspring.
- Dose selection rationale:
Dose levels were defined according to the results of preliminary test. More specifically, as a result of a 2-week repeated administration of the test article at dose levels of 100, 300 and 1000 mg/kg, no changes were seen with regards to general medical conditions, body weights, food consumption, hematology, blood biochemistry, autopsy and organ weights. Hence, for dose levels in this test, a high dose was defined to be 1000 mg/kg, which is a limit dose in conformity with OECD guideline; and similarly, medium and low doses were determined to be 300 and 100 mg/kg, respectively, which were obtained sequentially by dividing the high and medium doses by a common ratio of ca. 3.
- Rationale for animal assignment (if not random):
The stratified continuous random sampling method was adopted for grouping, based on body weights on the day before starting administration
- Post-exposure period: one day
Examinations
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS and DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: In all cases of both males and females, observation of general medical conditions and check of viability were conducted more than twice a day.
BODY WEIGHT: Yes
- Time schedule for examinations:
< Males were measured twice a week during administration period.
< Females were weighed twice a week during pre-mating administration and mating periods, on days 0 (the day when gestation was confirmed), 4, 7, 10, 14, 17 and 21 of gestation, and days 0 (parturition day) and 4 of lactation.
FOOD CONSUMPTION
< Food consumption of males was measured twice a week throughout the whole administration period except during mating period.
< As for females, that amount was measured twice a week during pre-mating administration period, on days 1, 4, 7, 10, 14, 17 and 21 of gestation, and on days 1 and 4 of lactation.
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- After the completion of administration period, all males were fasted for more than 18 hours, and then subjected to laparotomy under anesthesia by intraperitoneal administration of pentobarbital sodium, in order to collect blood from the abdominal caudal vena cava.
- The collected blood samples were treated with EDTA-2K (EDTA-2K-added blood) to measure
white blood cell count (Electrical resistance detection method),
red blood cell count (Electrical resistance detection method),
hemoglobin content (Oxyhemoglobin method),
hematocrit (Detection method for high-level hemocyte wave pulse) and
platelet count (Electrical resistance detection method),
using an automated multi-channel blood cell counter (SysmexCC-780, manufactured by Toa Medical Electronics); then
mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and
mean corpuscular hemoglobin concentration (MCHC) were obtained from these measured values.
CLINICAL CHEMISTRY: Yes
- Following the hematological examination, the collected blood samples were left standing at room temperature for approximately 60 minutes, then underwent centrifugation at 3000 rpm for 10 minutes;
- the serum samples thus obtained were measured for
total protein (Biuret method),
albumin (BCG method),
A/G ratio (obtained from total protein and albumin),
total billirubin (Alkaline azo-billirubin method),
GOT (Karmen method),
GPT (Wróblewski-La Due method),
γ-glutamyl trans-peptidase (γ-GTP, L-γ-glutamyl-DBHA substrate method),
alkaline phosphatase (p-nitrophenylphosphate substrate method),
total cholesterol (COD-DAOS method),
triglyceride (GPO-DAOS and glycerin elimination methods),
phospholipid (enzymatic and DAOS chromogenic methods),
glucose (Glucokinase/G-6-PDH method),
urea nitrogen (Urease-GIDH method),
creatinine (Jaffé method),
inorganic phosphorus (Molybdic acid direct method) and
calcium (OCPC method), using an automated analyzer (736-10, manufactured by Hitachi, Ltd.).
The serum samples were also measured for Na (Electrode method),
K (Electrode method) and
Cl (Coulometric titration method), using an electrolyte analyzer (PVA-α III, manufactured by Analytical Instruments).
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No
OTHER:
- All the females, in which copulation was confirmed, were subjected to spontaneous delivery, in order to observe the states of parturition (including signs of parturition) and lactation (including breast-feeding, nest building, etc.) and obtain gestation period and delivery rate [(Number of females which delivered live newborns/Number of gestated females) x 100].
- If an animal completed delivery by 0 p.m., the day was regarded as “parturition day”, and the same day was defined as day 0 of lactation. - Oestrous cyclicity (parental animals):
- Vaginal smears were collected at a certain time every morning from 14 days before the beginning of mating (the starting day of administration) to the day when copulation was confirmed, to examine sexual cycle.
- Sperm parameters (parental animals):
- Parameters examined in [all/P/F1/F2] male parental generations:
[testis weight, epididymis weight, daily sperm production, sperm count in testes, sperm count in epididymides, enumeration of cauda epididymal sperm reserve, sperm motility, sperm morphology, other:] - Litter observations:
- - As for offspring, numbers of offspring, live newborns and stillborns, as well as sex and external anomalies of live newborns were examined at parturition.
- In regard to live newborns, body weights were measured individually on the day of birth and day 4 of lactation; at the same time, birth index [(Number of live newborns/Number of implantation sites) x 100] and viability index of live newborns as of day 4 of lactation [Number of live offspring on day 4 of lactation/Number of live newborns] were obtained. - Postmortem examinations (parental animals):
- GROSS PATHOLOGY: Yes
- Following collection of blood samples after the completion of administration period in the case of males, or on day 4 of lactation in the case of females, rats were killed by exsanguination via transection of the external iliac artery under anesthesia with ether.
- Subsequently, they were dissected for gross observation of various organs and tissues; in addition, females were examined for numbers of corpus lutea and implantation sites.
- Following the autopsy, brain, heart, lungs (including bronchi), thymus, liver, spleen, kidneys, adrenal glands, testes, epididymes and ovaries were removed, in order to measure organ weights (absolute weights) and obtain the ratios of respective organs to body weight (relative weights) based on body weights on the day of autopsy.
- In addition to the weighed organs, gross abnormal sites were removed and fixed in a 10 %-neutral buffered formalin solution (testes and epididymes were prefixed in Bouin fluid).
HISTOPATHOLOGY: Yes
- As for control and 300 mg/kg groups, paraffin sections were prepared from brain, heart, lungs (including bronchi), thymus, liver, spleen, kidneys, adrenal glands, testes, epididymes and ovaries in the usual manner, in order to stain with hematoxylin and eosin (HE) and observe under a light microscope. - Additionally, one case with gross splenic hypertrophy in 100 mg/kg group was suspected of myelogenic leukemia; accordingly thigh bones (marrow), liver and mesenteric lymph nodes were also removed to conduct the same examination.
- Moreover, liver, spleen and thigh bones were stained with esterase. In the cases of death, kidneys and lungs were stained with PTAH.
- All gross abnormal sites (excluding inversions of intra-thoracic and intraperitoneal organs) underwent histopathological examination. - Postmortem examinations (offspring):
- GROSS NECROPSY and HISTOPATHOLOGY / ORGAN WEIGTHS
- On day 4 of lactation, all live newborns were killed by exsanguination under anesthesia with ether for gross observation of organs and tissues. - Statistics:
- For each group, mean value and standard deviation of body weights, food consumption, hematology, blood biochemistry, number of days required for copulation, sexual cycle (number of estrus, estrous cycle), organ weights, gestation period, numbers of corpus lutea, implantation sites, total offspring and live newborns, and body weights of live newborns were obtained. Then the uniformity of dispersion was tested first by using the Bartlett method between control group and each of other administration groups which were exposed to the test article. The Dunnett’s multiple comparison test (when the dispersion was uniform) and the Steel’s multiple comparison test (when the dispersion was not uniform) were used respectively to perform a comparison with control group. Likewise, the χ2 test for copulation rate, gestation index, delivery rate and sex ratio of live newborns, the Wilcoxon rank-sum test for stillbirth index, birth index and viability index of live newborns on day 4 of lactation, and the Mann-Whitney U test for pathology were used respectively to perform a comparison between control group and each of other administration groups. In each case, the levels of significance were set to 1 and 5 %. Incidentally, the measured values for live newborns were processed on a per-litter basis.
- Reproductive indices:
- copulation rate [(Number of copulated animals/Number of cohabited animals) x 100];
gestation index [(Number of gestated animals/Number of copulated animals) x 100];
delivery rate [(Number of females which delivered live newborns/Number of gestated females) x 100]. - Offspring viability indices:
- birth index [(Number of live newborns/Number of implantation sites) x 100];
viability index of live newborns as of day 4 of lactation [Number of live offspring on day 4 of lactation/Number of live newborns];
stillbirth index [(No. of stillborn pups)/(No. of live newborns)]
Results and discussion
Results: P0 (first parental generation)
Details on results (P0)
- With regard to males, no death occurred, and no changes in general medical conditions were seen in each group.
As for females, one case in 300 mg/kg group exhibited decreased activity, bradypnea, lowered body temperature and prone position from prior to administration on day 2 of lactation, and died on day 3 of lactation.
- In this case, no lactation activities were seen from day 2 of lactation when these symptoms developed, and histopathological examination revealed stress-related changes such as forestomach ulcer, glandular stomach erosion, thymic atrophy, and hypertrophy of adrenal zona glomerulosa and zona fasciculata; accordingly it was assumed that the female died because of puerperium. Moreover, in this case, focal necrosis of liver, pulmonary thrombus, epithelial cell necrosis of renal proximal tubule and hemorrhage into renal tubule were also seen. However, these changes were sometimes found in animals which died due to puerperal disease (NARAMA Isao, “Course in Toxicity Screening Test 5, Toxicologic Pathology”, edited by MAEKAWA Akihiko and HAYASHI Yuzo, Chijin Shokan Co., Ltd., Tokyo, 1992, p. 66) and thus considered to be related to puerperium. Hence, these changes were not considered to be related to administration of the test article.
- In 100 and 1000 mg/kg groups, no death occurred, and no changes in general medical conditions were seen.
- Therefore no effects of test article administration were assumed with regard to general medical conditions.
BODY WEIGHT AND FOOD CONSUMPTION (PARENTAL ANIMALS)
- As for males and females in each group, no differences were seen in comparison with control group throughout administration period.
REPRODUCTIVE FUNCTION: ESTROUS CYCLE (PARENTAL ANIMALS)
- According to examination of sexual cycle, no differences in number of estrus and estrous cycle were seen between each administration group and control group.
REPRODUCTIVE FUNCTION: SPERM MEASURES (PARENTAL ANIMALS)
- no data
REPRODUCTIVE PERFORMANCE (PARENTAL ANIMALS)
- According to examination of fertility, copulation was seen in all pairs except one in 100 mg/kg, and fertile ability was confirmed in each pair. Therefore, copulation rates were 100, 91.67, 100 and 100 %, respectively in control, 100, 300 and 1000 mg/kg groups, while gestation indices were 100 % in all groups; accordingly no differences were seen between each group and control group. Also with regard to number of days required for copulation, there were no differences between each group and control group. Incidentally, the non-copulated case showed no anomalies at autopsy and in histopathological examination of ovaries.
ORGAN WEIGHTS (PARENTAL ANIMALS)
- As for males, increases in absolute and relative weights of spleen were seen in 300 mg/kg group compared to control:
absolute spleen weight: 0.90 ± 0.07 g compared to 0.81 ± 0.08 g
relative spleen weight: 0.17 ± 0.01 g compared to 0.15 ± 0.02 g
- However, the same change was not seen in any females and other males in 1000 mg/kg group.
- Consequently, this change was considered to be incidental by the authors.
GROSS PATHOLOGY (PARENTAL ANIMALS)
- At autopsy in males after the completion of administration period, one case in 100 mg/kg group showed splenic hypertrophy and was histo-pathologically diagnosed with myelogenic leukemia. However, this kind of change was not seen in more than 300 mg/kg groups, and, while relatively rare, a similar change was reported as a spontaneous lesion in rats of the same type and the same-week old (C. B. Richter, Laboratory Investigation, 26, 419, 1972). Accordingly, this change was not considered to be related to administration of the test article.
- In addition, one case in 1000 mg/kg group showed a lymphocytic infiltrate beneath the endocardium of the left ventricle. However, its expression frequency was extremely low, and this kind of change was also reported as a spontaneous lesion in rats (NARAMA Isao, “Course in Toxicity Screening Test 5, Toxicologic Pathology”, edited by MAEKAWA Akihiko and HAYASHI Yuzo, Chijin Shokan Co., Ltd., Tokyo, 1992, p. 59). Therefore, this change was not considered to be related to administration of the test article.
- One case in 100 mg/kg group showed inversions of intra-thoracic and intraperitoneal organs.
- At autopsy in females on day 4 of lactation, no anomalies were seen in each group. Incidentally, one case in 300 mg/kg group, which died on day 3 of lactation, showed dark-red renal papilla, dark-red urine in bladder, blood pooling in vagina, dark-red spots in forestomach and glandular stomach mucosa. However, these changes were considered to be related to puerperium and not considered to be related to administration of the test article.
Therefore, for both, males and females no effects of test article administration were assumed with regard to pathology.
HISTOPATHOLOGY (PARENTAL ANIMALS)
Males
- One case in 1000 mg/kg group showed a lymphocytic infiltrate beneath the endocardium of the left ventricle.
- Additionally, one case with gross splenic hypertrophy in 100 mg/kg group was diagnosed with myelogenic leukemia, by reason of the following histological findings.
- More specifically, in this case, femoral bone marrow was dominated by tumor cells with a relatively light, round or oval nucleus which had very little cytoplasm; at the same time, similar tumor cells were found around the hepatic portal vein and showed diffuse growth in lobular sinusoid.
- Moreover, in spleen, tumor cells showed infiltrative growth over the entire region to replace the normal structure of spleen. No neoplastic changes were seen in mesenteric lymph nodes.
Females
- No organ changes were seen in each group.
- Incidentally, one case of death in 300 mg/kg group showed focal necrosis of liver, pulmonary thrombus, epithelial cell necrosis of renal proximal tubule and hemorrhage into renal tubule. In addition, forestomach ulcer, glandular stomach erosion, thymic atrophy, and hypertrophy of adrenal zona glomerulosa and zona fasciculata were found.
Effect levels (P0)
- Dose descriptor:
- NOAEL
- Effect level:
- > 1 000 mg/kg bw/day
- Sex:
- male/female
- Basis for effect level:
- other: No effets observed.
Results: F1 generation
Details on results (F1)
- According to examination at parturition, 300 mg/kg group showed increases in numbers of implantation sites, total offspring and live newborns.
However, the same changes were not found in 1000 mg/kg group; therefore these changes were not considered to be related to administration of the test article.
- According to examination during lactation period, there were no differences in viability index on day 4 of lactation between each administration group and control group.
CLINICAL SIGNS (OFFSPRING)
- no data
BODY WEIGHT (OFFSPRING)
- According to examination at parturition and during lactation period, there were no differences in body weights of live newborns between each administration group and control group.
SEXUAL MATURATION (OFFSPRING)
- no data
ORGAN WEIGHTS (OFFSPRING)
- no data
GROSS PATHOLOGY (OFFSPRING)
- no data
HISTOPATHOLOGY (OFFSPRING)
- no data
OTHER FINDINGS (OFFSPRING)
- According to examination at parturition, there were no differences in gestation period, number of corpus lutea, delivery rate, birth index, and stillbirth index between each administration group and control group; and no anomalies were found in external examination in each group.
Effect levels (F1)
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- > 1 000 mg/kg bw/day
- Sex:
- male/female
- Basis for effect level:
- other: No effets observed.
Overall reproductive toxicity
- Reproductive effects observed:
- not specified
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.